Outcomes of COVID-19 in patients with CLL: a multicenter international experienceAnthony R. Mato, José‐Ángel Hernández‐Rivas, Lindsey E. Roeker et al.|Blood|2020Cited by 318
Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitorsChristine E. Ryan, Matthew S. Davids, Matthew P. Cheng et al.|Blood Advances|2020Cited by 45
Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignanciesStephen Jun Fei Chong, Matthew S. Davids, Fen Zhu et al.|Journal of Clinical Investigation|2023Cited by 43
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S. Davids, Jennifer R. Brown, Caron A. Jacobson et al.|Journal of Clinical Oncology|2024Cited by 40
MAJIC: A Phase III Trial of Acalabrutinib + Venetoclax versus Venetoclax + Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaChristine E. Ryan, Lindsey E. Roeker, Matthew S. Davids et al.|Future Oncology|2022Cited by 35